Holen Sie sich die Stockscreener-App
31.94
3.60%
1.11
Handel nachbörslich:
31.50
-0.44
-1.38%
Schlusskurs vom Vortag:
$30.83
Offen:
$31.17
24-Stunden-Volumen:
648.75K
Relative Volume:
1.50
Marktkapitalisierung:
$1.62B
Einnahmen:
$400.79M
Nettoeinkommen (Verlust:
$-35.58M
KGV:
-45.08
EPS:
-0.7085
Netto-Cashflow:
$-15.09M
1W Leistung:
+9.05%
1M Leistung:
-3.04%
6M Leistung:
-6.09%
1J Leistung:
+17.17%
1-Tages-Spanne:
$31.17
$32.18
1-Wochen-Bereich:
$29.03
$32.18
52-Wochen-Spanne:
$23.15
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Firmenname
Immunocore Holdings Plc Adr
Sektor
Branche
Telefon
01235 5430281
Adresse
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
31.94 | 1.56B | 400.79M | -35.58M | -15.09M | -0.7085 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-07 | Hochstufung | UBS | Sell → Buy |
| 2025-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-18 | Fortgesetzt | Guggenheim | Neutral |
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2025-05-27 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Sell |
| 2024-10-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Eingeleitet | Needham | Buy |
| 2023-08-16 | Eingeleitet | CapitalOne | Overweight |
| 2023-07-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-30 | Eingeleitet | Guggenheim | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2022-12-16 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-30 | Eingeleitet | Barclays | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-08-08 | Eingeleitet | Cowen | Outperform |
| 2022-08-02 | Eingeleitet | BTIG Research | Buy |
| 2022-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-20 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Neutral |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immunocore Holdings Plc Adr Aktie (IMCR) Neueste Nachrichten
Immunocore Holdings stock: Precision Oncology Leader with ImmTAC Innovation - AD HOC NEWS
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Short Interest Down 15.4% in March - MarketBeat
Jefferies reiterates Hold on Immunocore stock amid competitor data By Investing.com - Investing.com South Africa
Immunocore (IMCR) upgraded to strong buy: Here's why - msn.com
Immunocore (IMCR) upgraded to strong buy: Here's what you should know - MSN
Jefferies downgrades Immunocore stock rating on revenue concerns - Investing.com
Jefferies downgrades Immunocore stock rating on revenue concerns By Investing.com - Investing.com South Africa
Insider sells 11,832 ADRs at Immunocore (NASDAQ: IMCR) in cashless exercise - Stock Titan
Immunocore at Leerink Conference: Strategic Growth and Innovation - Investing.com
Q1 Earnings Forecast for Immunocore Issued By HC Wainwright - Defense World
What is HC Wainwright's Estimate for Immunocore Q1 Earnings? - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
T. Rowe Price (IMCR) lists 3,041,904 ADRs, a 6.0% stake in Immunocore - Stock Titan
FY2027 EPS Estimates for Immunocore Cut by HC Wainwright - MarketBeat
Immunocore to present at upcoming investor conferences - GlobeNewswire Inc.
Immunocore (NASDAQ:IMCR) Price Target Raised to $75.00 at Needham & Company LLC - Defense World
Immunocore Q4 Earnings Call Highlights - Yahoo Finance
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates - Investing.com South Africa
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - Finviz
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations - Finviz
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y - Finviz
Earnings call transcript: Immunocore Holdings Q4 2025 reveals strong growth, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Immunocore Holdings Q4 2025 reveals strong growth, stock dips - Investing.com India
Immunocore earnings ahead as melanoma pipeline advances By Investing.com - Investing.com India
Immunocore earnings ahead as melanoma pipeline advances - Investing.com
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Finviz
Immunocore (NASDAQ:IMCR) CAO John Goll Sells 698 Shares - MarketBeat
Leger Tina Amber St Sells 1,000 Shares of Immunocore (NASDAQ:IMCR) Stock - MarketBeat
Immunocore (NASDAQ:IMCR) CEO Bahija Jallal Sells 11,474 Shares - MarketBeat
David Berman Sells 5,965 Shares of Immunocore (NASDAQ:IMCR) Stock - MarketBeat
[144] Immunocore Holdings plc SEC Filing - Stock Titan
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Immunocore Q4 2025 Earnings Call Transcript - MarketBeat
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
Immunocore Holdings PLC Sponsored ADR $IMCR Stock Holdings Lifted by Candriam S.C.A. - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Shares Sold by Principal Financial Group Inc. - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
GSK Gets EU Approval for Expanded Use of Nucala in COPD - Finviz
HC Wainwright Weighs in on Immunocore FY2030 Earnings - Defense World
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
HC Wainwright Predicts Immunocore FY2030 Earnings - MarketBeat
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU - The Globe and Mail
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study - Finviz
Immunocore Holdings (IMCR) is One of the Best Small Cap Stocks Ready to Explode in 2026 - Finviz
Immunocore announces resignation of head of research and development By Investing.com - Investing.com South Africa
Immunocore announces resignation of head of research and development - Investing.com
Immunocore announces executive leadership changes in R&D - Investing.com
Finanzdaten der Immunocore Holdings Plc Adr-Aktie (IMCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunocore Holdings Plc Adr-Aktie (IMCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jallal Bahija | CHIEF EXECUTIVE OFFICER |
Feb 17 '26 |
Option Exercise |
0.00 |
23,817 |
0 |
23,817 |
| Jallal Bahija | CHIEF EXECUTIVE OFFICER |
Feb 18 '26 |
Sale |
32.35 |
11,474 |
371,184 |
12,343 |
| GOLL JOHN | SVP, FINANCE & CAO |
Feb 17 '26 |
Option Exercise |
0.00 |
1,351 |
0 |
1,351 |
| GOLL JOHN | SVP, FINANCE & CAO |
Feb 18 '26 |
Sale |
32.35 |
698 |
22,580 |
653 |
| St Leger Tina Amber | CHIEF HR OFFICER |
Feb 17 '26 |
Option Exercise |
0.00 |
2,119 |
0 |
2,119 |
| St Leger Tina Amber | CHIEF HR OFFICER |
Feb 18 '26 |
Sale |
32.35 |
1,000 |
32,350 |
1,119 |
| Berman David M | HEAD OF R&D |
Feb 17 '26 |
Option Exercise |
0.00 |
11,824 |
0 |
11,824 |
| Berman David M | HEAD OF R&D |
Feb 18 '26 |
Sale |
32.35 |
5,965 |
192,968 |
5,859 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):